Abiodun Lofton, | |
9903 Oxbridge Way, Bowie, MD 20721-2975 | |
(301) 925-2980 | |
Not Available |
Full Name | Abiodun Lofton |
---|---|
Gender | Female |
Speciality | Licensed Vocational Nurse |
Location | 9903 Oxbridge Way, Bowie, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1265602700 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164X00000X | Licensed Vocational Nurse | (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Abiodun Lofton, 9903 Oxbridge Way, Bowie, MD 20721-2975 Ph: (301) 925-2980 | Abiodun Lofton, 9903 Oxbridge Way, Bowie, MD 20721-2975 Ph: (301) 925-2980 |
News Archive
GE Money, the consumer lending unit of General Electric Company, and Nautilus, Inc., a global fitness equipment leader, today announced a multi-year agreement to provide consumer financing via Nautilus' direct sales channel.
Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb Company and Pfizer Inc., was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing elective total knee replacement surgery, according to the ADVANCE-2 study results published today in The Lancet. The study results also showed numerically lower rates of major and clinically relevant non-major bleeding in patients treated with apixaban compared with those treated with enoxaparin.
Women and men look at faces and absorb visual information in different ways, which suggests there is a gender difference in understanding visual cues, according to a team of scientists that included psychologists from Queen Mary University of London.
In late-breaking clinical trial results presented in a Hot Line Session today at the European Society of Cardiology Congress 2019, investigators from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris presented the results from The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study, a clinical trial sponsored by AstraZeneca that evaluated whether adding ticagrelor to aspirin improves outcomes for patients with stable coronary artery disease and diabetes mellitus but without a history of heart attack or stroke.
› Verified 4 days ago